Yüklüyor......
Ipilimumab: A potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer
Immunotherapy has garnered an important place in the therapeutic landscape of treatment in prostate cancer since approval of sipuleucel-T. Ipilimumab is a checkpoint inhibitor that is currently approved for the treatment of advanced melanoma. In the June issue of Lancet Oncology, Kwon and colleagues...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Landes Bioscience
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4130722/ https://ncbi.nlm.nih.gov/pubmed/25046606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.29928 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|